WO2008028926A3 - Methods and compositions for the prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia - Google Patents
Methods and compositions for the prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia Download PDFInfo
- Publication number
- WO2008028926A3 WO2008028926A3 PCT/EP2007/059283 EP2007059283W WO2008028926A3 WO 2008028926 A3 WO2008028926 A3 WO 2008028926A3 EP 2007059283 W EP2007059283 W EP 2007059283W WO 2008028926 A3 WO2008028926 A3 WO 2008028926A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- prediction
- compositions
- response
- chemotherapy regimen
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009104 chemotherapy regimen Methods 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 229960000575 trastuzumab Drugs 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000008711 chromosomal rearrangement Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000009452 underexpressoin Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/440,490 US20090280493A1 (en) | 2006-09-08 | 2007-09-04 | Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia |
EP07803246A EP2064339A2 (en) | 2006-09-08 | 2007-09-05 | Methods and compositions for the prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06018836.4 | 2006-09-08 | ||
EP06018836 | 2006-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008028926A2 WO2008028926A2 (en) | 2008-03-13 |
WO2008028926A3 true WO2008028926A3 (en) | 2008-07-10 |
Family
ID=39052831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/059283 WO2008028926A2 (en) | 2006-09-08 | 2007-09-05 | Methods and compositions for the prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia |
Country Status (3)
Country | Link |
---|---|
US (1) | US20090280493A1 (en) |
EP (1) | EP2064339A2 (en) |
WO (1) | WO2008028926A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2552937T3 (en) * | 2008-06-06 | 2015-12-03 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Survival prediction factor for diffuse large B-cell lymphoma |
CN106153918A (en) * | 2008-10-14 | 2016-11-23 | 卡里斯Mpi公司 | Describe tumor type biological marker pattern and the gene target of feature set and the protein targets of gene expression |
WO2010118782A1 (en) * | 2009-04-17 | 2010-10-21 | Universite Libre De Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
CA2779223A1 (en) * | 2009-10-27 | 2011-05-12 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
US9677139B2 (en) | 2009-12-11 | 2017-06-13 | Cold Spring Harbor Laboratory | Genetic markers indicative of a cancer patient response to trastuzumab (herceptin) |
WO2011072205A2 (en) * | 2009-12-11 | 2011-06-16 | Cold Spring Harbor Laboratory | Genetic markers indicative of a cancer patient response to trastuzumab (herceptin) |
KR20130056855A (en) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | Biomarkers for theranostics |
BR112012025593A2 (en) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | circulating biomarkers for disease |
US20120077198A1 (en) * | 2010-07-30 | 2012-03-29 | Ambergen, Inc | Compositions And Methods For Cancer Testing |
US20130282390A1 (en) * | 2012-04-20 | 2013-10-24 | International Business Machines Corporation | Combining knowledge and data driven insights for identifying risk factors in healthcare |
CN102680709B (en) * | 2012-05-14 | 2014-05-21 | 上海交通大学 | Diagnostic kit and application of coiled-coil domain containing protein 49 (CCDC49) in preparing gastric cancer early-stage diagnostic reagent |
WO2014203918A1 (en) * | 2013-06-19 | 2014-12-24 | 学校法人 久留米大学 | Method of predicting therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors |
CN103305515B (en) * | 2013-06-28 | 2015-03-25 | 哈尔滨医科大学 | Family with sequence similarity 84, member B (FAM84B) antisense nucleotide and application thereof |
US20160060707A1 (en) * | 2014-08-29 | 2016-03-03 | Immunomedics, Inc. | Identification of Cancer Genes by In-Vivo Fusion of Human Cancer Cells and Animal Cells |
US10871539B2 (en) * | 2014-11-24 | 2020-12-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Determination of a joint probability distribution of radius and length of anisotropic pores from double pulsed field gradient MRI data |
US11674182B2 (en) | 2017-03-08 | 2023-06-13 | Industry-University Cooperation Foundation Hanyang University | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof |
CN113265463B (en) * | 2021-04-15 | 2023-02-28 | 山西医科大学 | Application of FAM84B in preparation of esophageal squamous carcinoma prognosis evaluation reagent and screening of drugs for targeted therapy of esophageal squamous carcinoma |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1365034A2 (en) * | 2002-05-21 | 2003-11-26 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
WO2005047534A2 (en) * | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Methods and compositions for the response prediction of malig-nant neoplasia to treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090298061A1 (en) * | 2005-07-29 | 2009-12-03 | Siemens Healthcare Diagnostics Inc. | Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy |
WO2007015947A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
-
2007
- 2007-09-04 US US12/440,490 patent/US20090280493A1/en not_active Abandoned
- 2007-09-05 EP EP07803246A patent/EP2064339A2/en not_active Withdrawn
- 2007-09-05 WO PCT/EP2007/059283 patent/WO2008028926A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1365034A2 (en) * | 2002-05-21 | 2003-11-26 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
WO2005047534A2 (en) * | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Methods and compositions for the response prediction of malig-nant neoplasia to treatment |
Non-Patent Citations (1)
Title |
---|
VAN DEKKEN H ET AL: "Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.", CANCER RESEARCH 1 FEB 1999, vol. 59, no. 3, 1 February 1999 (1999-02-01), pages 748 - 752, XP002470245, ISSN: 0008-5472 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
Also Published As
Publication number | Publication date |
---|---|
EP2064339A2 (en) | 2009-06-03 |
WO2008028926A2 (en) | 2008-03-13 |
US20090280493A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008028926A3 (en) | Methods and compositions for the prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia | |
WO2007123772A3 (en) | Genes involved in estrogen metabolism | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2007006408A3 (en) | Methods and kits for predicting and monitoring direct response to cancer therapy | |
WO2007112330A3 (en) | Compositions and methods for detection, prognosis and treatment of colon cancer | |
WO2008117314A3 (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2007081680A3 (en) | Microrna expression abnormalities in pancreatic endocrine and acinar tumors | |
WO2008008430A3 (en) | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases | |
WO2008153705A3 (en) | Methods of treating, diagnosing and detecting fgf21-associated disorders | |
WO2007044413A3 (en) | Wwox gene, vectors containing the same, and uses in treatment of cancer | |
WO2012068383A3 (en) | ncRNA AND USES THEREOF | |
WO2009002931A3 (en) | Methods and uses thereof of prosaposin | |
EP1937845A4 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
WO2007109236A3 (en) | Microrna fingerprints during human megakaryocytopoiesis | |
WO2008046509A8 (en) | Ltbp2 as a biomarker, therapeutic and diagnostic target | |
WO2007064776A3 (en) | Markers for breast cancer | |
EP2487257A3 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
WO2012174256A3 (en) | Dna methylation profiles in cancer | |
WO2008104543A3 (en) | Method for predicting the occurrence of metastasis in breast cancer patients | |
WO2005119260A3 (en) | Methods for predicting and monitoring response to cancer therapy | |
WO2010004591A3 (en) | Genetic variants for breast cancer risk assessment | |
WO2005044990A3 (en) | Use of differentially expressed nucleic acid sequences as biomarkers for cancer | |
WO2007058968A3 (en) | Gene expression profiles and methods of use | |
WO2008115750A3 (en) | Compositions and methods for the treatment of cancer | |
WO2008088860A3 (en) | Polymorphisms in the egfr pathway as markers for cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07803246 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007803246 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12440490 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |